Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).

Lori J WirthMakoto TaharaBruce RobinsonSanjeev FrancisMarcia S BroseMouhammed Amir HabraKate NewboldNaomi KiyotaCorina E DutcusElton MathiasMatthew GuoSteven I ShermanMartin Schlumberger

Published in: Cancer (2018)

Although HTN is a clinically significant adverse event that warrants monitoring and management, TE-HTN was significantly correlated with improved outcomes in patients with RR-DTC, indicating that HTN may be predictive for lenvatinib efficacy in this population. Cancer 2018;124:2365-72. © 2018 American Cancer Society.

Keyphrases

papillary thyroid
squamous cell
lymph node metastasis
clinical trial
emergency department
squamous cell carcinoma
young adults
open label
drug induced